TABLE 8.

Protection of monkeys immunized with different ChimeriVax-DEN1-4 tetravalent formulations and challenged with heterologous WT DEN2 virus^a

Group	Monkey	Vaccine formulation	Viremia by day postchallenge:										PRNT50
			2	3	4	5	6	7	8	9	10	11	Prechallengec	Postchallenged
7	F212117F	3,5,5,3	0b	0	0	0	0	0	0	0	0	0	20	640
	F21342M	5,5,5,3	0	0	0	0	0	0	0	0	0	0	80	5,120
	F21786F	5,5,5,5	0	0	0	0	0	0	0	0	0	0	160	1,280
	F21384F	5,5,5,3	0	0	0	0	0	0	0	0	0	0	80	2,560
	F21544M	5,5,5,3	0	0	0	0	0	0	0	0	0	0	<10	1,280
	F21386F	5,5,5,5	0	0	0	0	0	0	0	0	0	0	40	640
8	F22605M	None	0	0	0	0	0	0	2.0	2.5	2.7	2.2	<10	80
	F226100F	None	0	0	0	0	0	1.0	2.5	2.3	0	0	<10	2,560
	F21563F	None	0	0	0	0	1.7	2.4	2.0	2.3	3.0	1.7	<10	1,280
	F21550M	None	0	0	0	0	0	1.3	1.3	1.0	1.8	1.6	<10	320

^aAll monkeys were challenged with 5 log units of DEN2 virus (S16803) PDK10, with the exception of monkeys F22605M and F226100F, which received 4 log units of challenge virus (pilot study). The day of challenge was considered day 1 for comparative purposes.

^b-dSee Table 7, footnotes b to d.